The MSCP SPORE Developmental Research Program (DRP) provides seed funding to explore promising novel research in melanoma and other skin cancers, particularly by investigators not currently engaged in research in this area. The DRP solicits proposals twice a year and to use a peer-reviewed scoring system to prioritize proposals for funding. The DRP Directors and Executive Committee, Internal Advisory Board and External Advisory Board participate in the review process, together with the Patient Advocates and any additional experts who may be called upon if special reviewer expertise is necessary. During the past grant period, the MSCP SPORE funded 9 DRP projects in basic, translational, and clinical research. The DRP Directors track the progress of the successful applications and assign mentors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A, Biospecimen Core B, Biostatistics Core C, and Informatics Core D) and that they are effectively integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of funding to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether DRP projects are found to merit promotion to full SPORE projects;in the past funding period, productive and innovative research funded by DRP awards to Drs. Hassane Zarour and Soldano Ferrone has been promoted to a full project. Project 3, in this renewal application. Awardees are also advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE Core resources to aid in this endeavor. DRP-supported research has led to 3 NCI awards (R01CA154728, R01CA157467, R01CA169118) and a pilot award funded by the University of Pittsburgh Clinical Translational Science Institute Basic to Clinical Collaborative Research Pilot Program. There are also several grant applications submitted or planned based on DRP results from the previous grant period, including an R21 and two additional R01 applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-07
Application #
8933154
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2006-07-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$65,722
Indirect Cost
$23,482
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Hoot, Joyce W; Wang, Li; Kho, Terry et al. (2018) The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. J Dermatolog Treat 29:272-276
Anderson, Alyce J M; Ferris, Laura K; Binion, David G et al. (2018) Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci 63:2564-2572
Geskin, Larisa J; Damiano, James J; Patrone, Christina C et al. (2018) Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res 28:211-221
Geskin, Larisa J; Akilov, Oleg E; Kwon, Soonyou et al. (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67:423-434
Davar, Diwakar; Wang, Hong; Chauvin, Joe-Marc et al. (2018) Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol :JCO1800632
Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739
Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366

Showing the most recent 10 out of 209 publications